2 assets in Familial Ovarian Carcinoma

Therapeutic assets addressing Familial Ovarian Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dostarlimab Familial Ovarian Carcinoma	University of Washington	P1	CC (43)
Niraparib Familial Ovarian Carcinoma	University of Washington	P1	CC (43)